Aronora

Aronora Aronora is a small biopharmaceutical company developing safe biological drugs.

Our treatments do not have the bleeding side effects of all currently marketed antithrombotics. Pipeline includes an antibody that selectively reduces the procoagulant activity of the contact coagulation factor XII (F12) and may attenuate consumptive coagulopathy (DIC) that is often associated with life-threatening severe infections including sepsis or RNA viral hemorrhagic fevers associated with Dengue, Marburg, Ebola, Lassa, etc.

“The venture arm is also a way for NYBC to apply its experience and capital to advance technologies for underserved area...
05/18/2023

“The venture arm is also a way for NYBC to apply its experience and capital to advance technologies for underserved areas of medicine…it is finalizing a deal to invest $2m in Aronora. A company developing drugs for blood diseases…generally raising venture capital in this field is difficult because of the perception that startups would need giant clinical studies to prove their drugs are effective in a range of patients who need anti clotting therapies…a startup can break into the market by targeting a narrower slice of the broad population… Aronora is developing its lead drug in patients on dialysis who can’t tolerate blood thinners…”

New York Blood Center and other healthcare nonprofits are using venture capital to help startups tackle diseases.

Out website got a facelift. :) www.aronorabio.com
09/27/2021

Out website got a facelift. :) www.aronorabio.com

PARADIGM SHIFTING DRUGS FOR LIFE-THREATENING BLOOD DISEASES PARADIGM SHIFTING DRUGS FOR BLOOD DISEASES FIRST-IN-CLASS SAFE BIOLOGIC DRUGS Aronora is committed to developing and commercializing safe, first-in-class medicines for blood diseases with significant unmet medical need. MORE ABOUT US FIRST-...

We love our new home! Thank you SmithArnold Inc.
09/03/2021

We love our new home! Thank you SmithArnold Inc.

“The problem we are having is that while we understand that there is a clot, we don’t yet understand why there is a clot...
04/28/2020

“The problem we are having is that while we understand that there is a clot, we don’t yet understand why there is a clot,” Kaplan said. “We don’t know. And therefore, we are scared.”

Once thought to be a relatively straightforward respiratory virus, covid-19 is proving to be much more complex and frightening

Dr. Thomas Oxley, a neurosurgeon at Mount Sinai Health System in New York, and colleagues gave details of five people th...
04/23/2020

Dr. Thomas Oxley, a neurosurgeon at Mount Sinai Health System in New York, and colleagues gave details of five people they treated. All were under the age of 50, and all had either mild symptoms of Covid-19 infection or no symptoms at all.
"The virus seems to be causing increased clotting in the large arteries, leading to severe stroke," Oxley told CNN.

The new coronavirus appears to be causing sudden strokes in adults in their 30s and 40s who are not otherwise terribly ill, doctors reported Wednesday.

Not all strokes look the same...
01/03/2020

Not all strokes look the same...

After the 67-year-old woman fell at the airport, the left side of her body wouldn’t cooperate. The answer to her malady was found in her heart.

Interesting.
11/22/2019

Interesting.

WASHINGTON (AP) — They still bite, but new research shows lab-grown mosquitoes are fighting dangerous dengue fever that they normally would spread. Dengue infections appear to be dropping...

A nice mention for us in Willamette Week and an assessment of the startup climate in Portland Oregon, the 21st most entr...
07/12/2019

A nice mention for us in Willamette Week and an assessment of the startup climate in Portland Oregon, the 21st most entrepreneurial city, a 10-rank increase from the previous year and one of the largest year-by-year increases according a Kauffman Foundation study.

This spring, Oregon almost saw its first unicorn. A “unicorn” is a company that sells for $1 billion. In May, an Oregon company almost did just that: Cura Cannabis was acquired by a Canadian company for $949 million in stock.

Thanks for the shout out BioSpace ! Aronora is proud to be a part of the Oregon life science community.
06/06/2019

Thanks for the shout out BioSpace ! Aronora is proud to be a part of the Oregon life science community.

The Oregon Bioscience Association recently released a new economic impact report, showing that the state’s biopharma and life science industry is continuing to grow at a significant clip.

Address

1818 SW 4th Avenue Suite 102
Portland, OR
97201

Opening Hours

Monday 8am - 5pm
Tuesday 8am - 5pm
Wednesday 8am - 5pm
Thursday 8am - 5pm
Friday 8am - 5pm
Saturday 8am - 5pm
Sunday 8am - 5pm

Telephone

+15035306842

Alerts

Be the first to know and let us send you an email when Aronora posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Aronora:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram